Twist Bioscience Corporation APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Twist Bioscience Corporation (TWST) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $18.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- Twist Bioscience Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $18.18M, a 13.06% increase year-over-year.
- Twist Bioscience Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $18.95M, a 6.72% decline year-over-year.
- Twist Bioscience Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $13.29M, a 10.48% increase year-over-year.
- Twist Bioscience Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $16.09M, a 30.10% increase year-over-year.
- Twist Bioscience Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $64.50M, a 26.46% increase from fiscal 2024.
- Twist Bioscience Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $51.01M, a 65.49% increase from fiscal 2023.
- Twist Bioscience Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $30.82M, a 61.31% decline from fiscal 2022.
- Twist Bioscience Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $79.66M, a 115.32% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.18M 10-Q · filed 2026-08-03 | $37.12M derived: sum of 2 quarters · filed 2026-08-03 | $50.41M 10-Q · filed 2026-08-03 | $66.50M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $18.95M 10-Q · filed 2026-05-04 | $32.24M 10-Q · filed 2026-05-04 | $48.33M derived: sum of 3 quarters · filed 2026-05-04 | $64.40M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $13.29M 10-Q/A · filed 2026-02-26 | $29.38M derived: sum of 2 quarters · filed 2026-02-26 | $45.45M derived: sum of 3 quarters · filed 2026-08-03 | $65.77M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | $16.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $32.16M derived: sum of 2 quarters · filed 2026-08-03 | $52.48M derived: sum of 3 quarters · filed 2026-08-03 | $64.50M 10-K · filed 2025-11-17 |
| 2025-06-30 | $16.08M 10-Q · filed 2026-08-03 | $36.39M derived: sum of 2 quarters · filed 2026-08-03 | $48.42M 10-Q · filed 2026-08-03 | $60.78M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $20.31M 10-Q · filed 2026-05-04 | $32.34M 10-Q · filed 2026-05-04 | $44.71M derived: sum of 3 quarters · filed 2026-05-04 | $58.45M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $12.03M 10-Q/A · filed 2026-02-26 | $24.39M derived: sum of 2 quarters · filed 2026-02-26 | $38.14M derived: sum of 3 quarters · filed 2026-02-26 | $51.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | $12.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $26.11M derived: sum of 2 quarters · filed 2025-11-17 | $39.96M derived: sum of 3 quarters · filed 2025-11-17 | $51.01M 10-K · filed 2025-11-17 |
| 2024-06-30 | $13.75M 10-Q · filed 2025-08-04 | $27.59M derived: sum of 2 quarters · filed 2025-08-04 | $38.64M 10-Q · filed 2025-08-04 | $50.45M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | $13.85M 10-Q · filed 2025-05-05 | $24.90M 10-Q · filed 2025-05-05 | $36.70M derived: sum of 3 quarters · filed 2025-11-17 | $47.36M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | $11.05M 10-Q · filed 2025-02-03 | $22.85M derived: sum of 2 quarters · filed 2025-11-17 | $33.52M derived: sum of 3 quarters · filed 2025-11-17 | $43.94M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | $11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $22.47M derived: sum of 2 quarters · filed 2025-11-17 | $32.90M derived: sum of 3 quarters · filed 2025-11-17 | $30.82M 10-K · filed 2025-11-17 |
| 2023-06-30 | $10.66M 10-Q · filed 2024-08-02 | $21.09M derived: sum of 2 quarters · filed 2024-08-02 | $19.02M 10-Q · filed 2024-08-02 | $38.06M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | $10.43M 10-Q · filed 2024-05-02 | $8.35M 10-Q · filed 2024-05-02 | $27.40M derived: sum of 3 quarters · filed 2024-11-18 | $47.44M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | -$2.07M 10-Q · filed 2024-02-02 | $16.97M derived: sum of 2 quarters · filed 2024-11-18 | $37.02M derived: sum of 3 quarters · filed 2024-11-18 | $59.48M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | $19.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $39.09M derived: sum of 2 quarters · filed 2024-11-18 | $61.56M derived: sum of 3 quarters · filed 2024-11-18 | $79.66M 10-K · filed 2024-11-18 |
| 2022-06-30 | $20.04M 10-Q · filed 2023-08-07 | $42.51M derived: sum of 2 quarters · filed 2023-08-07 | $60.62M 10-Q · filed 2023-08-07 | $69.86M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | $22.46M 10-Q · filed 2023-05-08 | $40.57M 10-Q · filed 2023-05-08 | $49.82M derived: sum of 3 quarters · filed 2023-11-21 | $59.00M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | $18.11M 10-Q · filed 2023-02-07 | $27.36M derived: sum of 2 quarters · filed 2023-11-21 | $36.53M derived: sum of 3 quarters · filed 2023-11-21 | $48.08M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | $9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $18.42M derived: sum of 2 quarters · filed 2023-11-21 | $29.98M derived: sum of 3 quarters · filed 2023-11-21 | $37.00M 10-K · filed 2023-11-21 |
| 2021-06-30 | $9.18M 10-Q · filed 2022-08-08 | $20.73M derived: sum of 2 quarters · filed 2022-08-08 | $27.75M 10-Q · filed 2022-08-08 | $32.88M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | $11.55M 10-Q · filed 2022-05-06 | $18.57M 10-Q · filed 2022-05-06 | $23.70M derived: sum of 3 quarters · filed 2023-06-05 | $27.78M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $7.02M 10-Q · filed 2022-02-09 | $12.15M derived: sum of 2 quarters · filed 2023-06-05 | $16.23M derived: sum of 3 quarters · filed 2023-06-05 | $20.42M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | $5.13M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $9.20M derived: sum of 2 quarters · filed 2023-06-05 | $13.40M derived: sum of 3 quarters · filed 2023-06-05 | $17.10M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $4.07M 10-Q · filed 2021-08-09 | $8.27M derived: sum of 2 quarters · filed 2021-08-09 | $11.96M 10-Q · filed 2021-08-09 | $15.33M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $4.20M 10-Q · filed 2021-05-07 | $7.89M 10-Q · filed 2021-05-07 | $11.26M derived: sum of 3 quarters · filed 2021-11-23 | $14.29M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $3.70M 10-Q · filed 2021-02-09 | $7.06M derived: sum of 2 quarters · filed 2021-11-23 | $10.09M derived: sum of 3 quarters · filed 2021-11-23 | $13.00M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $6.39M derived: sum of 2 quarters · filed 2021-11-23 | $9.31M derived: sum of 3 quarters · filed 2021-11-23 | $11.17M 10-K · filed 2021-11-23 |
| 2019-06-30 | $3.03M 10-Q · filed 2020-08-12 | $5.94M derived: sum of 2 quarters · filed 2020-08-12 | $7.81M 10-Q · filed 2020-08-12 | $8.89M derived: sum of 4 quarters · filed 2020-11-27 |
| 2019-03-31 | $2.91M 10-Q · filed 2020-05-13 | $4.78M 10-Q · filed 2020-05-13 | $5.86M derived: sum of 3 quarters · filed 2020-11-27 | $6.46M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | $1.86M 10-Q · filed 2020-02-10 | $2.95M derived: sum of 2 quarters · filed 2020-11-27 | $3.55M derived: sum of 3 quarters · filed 2020-11-27 | $4.29M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | $1.69M derived: sum of 2 quarters · filed 2020-11-27 | $2.42M derived: sum of 3 quarters · filed 2020-11-27 | $2.96M 10-K · filed 2020-11-27 |
| 2018-06-30 | $603.00K 10-Q · filed 2019-08-09 | $1.34M derived: sum of 2 quarters · filed 2019-08-09 | $1.88M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $736.00K 10-Q · filed 2019-05-02 | $1.27M 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | $536.00K 10-Q · filed 2019-02-11 | |||
| 2017-09-30 | $1.89M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |